Cytokinetics (CYTK) Total Debt (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Total Debt of $292.0 million for Q1 2026, up 178.15% year-over-year from $105.0 million in Q1 2025, and up 1.55% quarter-over-quarter from $287.6 million in Q4 2025.
Cytokinetics (CYTK) Total Debt (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Total Debt for 15 consecutive years, with $292.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Debt rose 178.15% year-over-year to $292.0 million; the TTM figure through Mar 2026 stood at $292.0 million (up 178.15% YoY), while the FY2025 annual figure was $287.6 million, up 174.53% from the prior year.
- Total Debt climbed to $292.0 million in Q1 2026 per CYTK's latest filing, from $287.6 million in the prior quarter.
- Across five years, Total Debt topped out at $292.0 million in Q1 2026 and bottomed at $60.9 million in Q3 2023.
- Historically, Total Debt has averaged $113.2 million across 5 years, with a median of $68.5 million in 2023.
- Annual changes were most pronounced in 2023 — Total Debt declined 4.18% — and 2026, when it jumped 178.15%.
- Cytokinetics' Total Debt stood at $64.8 million in 2022, then gained by 5.71% to $68.5 million in 2023, then surged by 53.0% to $104.7 million in 2024, then soared by 174.53% to $287.6 million in 2025, then increased by 1.55% to $292.0 million in 2026.
- Business Quant data shows CYTK's Total Debt at $292.0 million in Q1 2026, $287.6 million in Q4 2025, and $176.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | 275.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 275.56 Mn |
| Mar 31, 2026 | 292.02 Mn |
| Dec 31, 2025 | 287.57 Mn |
| Sep 30, 2025 | 176.03 Mn |
| Jun 30, 2025 | 173.46 Mn |
| Mar 31, 2025 | 104.99 Mn |
| Dec 31, 2024 | 104.75 Mn |
| Sep 30, 2024 | 104.54 Mn |
| Jun 30, 2024 | 104.35 Mn |
| Mar 31, 2024 | 68.34 Mn |
| Dec 31, 2023 | 68.46 Mn |
| Sep 30, 2023 | 60.89 Mn |
| Jun 30, 2023 | 62.49 Mn |
| Mar 31, 2023 | 64.11 Mn |
| Dec 31, 2022 | 64.77 Mn |
| Sep 30, 2022 | 63.54 Mn |
| Jun 30, 2022 | 62.34 Mn |
| Mar 31, 2022 | 61.17 Mn |
| Dec 31, 2021 | 47.37 Mn |
| Sep 30, 2021 | 47.08 Mn |